• In August 2026, Doximity, Inc. reported first-quarter revenue of US$156.62 million, up from US$145.91 million a year earlier, while net income fell to US$24.32 million from US$53.32 million, and the company issued guidance calling for second-quarter revenue of US$170–171 million and full-year revenue of US$671–681 million.
• Management highlighted surging adoption of its AI-powered clinical tools, independent validation of its Ask product’s safety and accuracy, and growing enterprise AI client wins as key drivers behind the updated revenue outlook.
• We’ll now examine how Doximity’s accelerating AI tool adoption and updated full-year revenue guidance shape its broader investment narrative.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Doximity Investment Narrative Recap

To own Doximity, you need to believe its physician network can increasingly monetize workflow and AI tools without undermining its core pharma marketing engine. The latest results show modest revenue growth but sharply lower net income, so the key near term catalyst remains whether AI adoption can translate into higher quality, recurring enterprise revenue. The biggest risk is that rising AI and compliance spend compresses margins further. This quarter’s news does not remove that concern.

The most relevant update is Doximity’s new full year revenue guidance of US$671 million to US$681 million. This frames how management sees AI driven demand offsetting margin pressure and any softness in pharma marketing budgets. For investors tracking near term catalysts, this range is now the reference point for judging whether AI tools, hospital adoption and new workflow modules are gaining enough commercial traction to justify the heavier investment showing up in weaker earnings.

Yet beneath the excitement around AI tools, investors should also be aware of the growing risk that rising costs and policy shifts could...

Doximity's narrative projects $786.6 million revenue and $219.9 million earnings by 2029.

Uncover how Doximity's forecasts yield a $28.00 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already assuming slower revenue growth of about 4.4 percent a year and shrinking margins, so this AI fueled update may either soften or reinforce their more cautious view depending on how you weigh today’s US$156.62 million quarter against those earlier expectations for about US$733.8 million of revenue and US$166.9 million of earnings by 2029.

Explore 4 other fair value estimates on Doximity - why the stock might be worth 27% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Doximity research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.